Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Average Rating of “Moderate Buy” by Brokerages

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) has received an average recommendation of “Moderate Buy” from the twelve brokerages that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, four have given a hold recommendation and seven have given a buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $36.00.

A number of analysts have issued reports on the company. HC Wainwright lowered their target price on Arcturus Therapeutics from $12.00 to $9.00 and set a “neutral” rating on the stock in a report on Tuesday, November 11th. Guggenheim downgraded shares of Arcturus Therapeutics from a “buy” rating to a “neutral” rating in a report on Wednesday, October 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of Arcturus Therapeutics in a research note on Wednesday, October 8th. Piper Sandler decreased their price objective on Arcturus Therapeutics from $140.00 to $72.00 and set an “overweight” rating on the stock in a report on Tuesday, November 11th. Finally, Zacks Research cut Arcturus Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 24th.

Arcturus Therapeutics Trading Down 3.4%

Shares of Arcturus Therapeutics stock opened at $7.20 on Wednesday. The firm has a fifty day simple moving average of $11.95 and a 200-day simple moving average of $13.98. The stock has a market capitalization of $204.55 million, a price-to-earnings ratio of -2.93 and a beta of 2.10. Arcturus Therapeutics has a 1-year low of $5.85 and a 1-year high of $24.17.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its earnings results on Monday, November 10th. The biotechnology company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($1.09) by $0.60. Arcturus Therapeutics had a negative net margin of 68.35% and a negative return on equity of 28.68%. The firm had revenue of $17.15 million for the quarter, compared to the consensus estimate of $17.47 million. As a group, research analysts predict that Arcturus Therapeutics will post -2.22 earnings per share for the current year.

Hedge Funds Weigh In On Arcturus Therapeutics

A number of hedge funds have recently modified their holdings of the stock. US Bancorp DE grew its position in Arcturus Therapeutics by 218.9% in the first quarter. US Bancorp DE now owns 3,393 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 2,329 shares during the period. Vanguard Group Inc. grew its position in Arcturus Therapeutics by 3.8% during the 1st quarter. Vanguard Group Inc. now owns 1,748,928 shares of the biotechnology company’s stock worth $18,521,000 after acquiring an additional 64,367 shares during the last quarter. Deutsche Bank AG raised its position in Arcturus Therapeutics by 10.1% in the 1st quarter. Deutsche Bank AG now owns 27,280 shares of the biotechnology company’s stock valued at $289,000 after purchasing an additional 2,512 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in shares of Arcturus Therapeutics by 9.2% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 14,693 shares of the biotechnology company’s stock worth $156,000 after purchasing an additional 1,232 shares during the last quarter. Finally, Invesco Ltd. increased its stake in shares of Arcturus Therapeutics by 83.1% in the first quarter. Invesco Ltd. now owns 34,896 shares of the biotechnology company’s stock valued at $370,000 after buying an additional 15,836 shares in the last quarter. 94.54% of the stock is owned by institutional investors and hedge funds.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.